Cepmed supports high-impact research intended to advance personalized medicine technology and the adoption of personalized medicine. Our impact is measured financially and socially, through the private funds we attract in our public-private partnerships, through changes in policy, health-care provider behaviour, as well as through overall health outcomes and costs savings to the Canadian healthcare system. Cepmed is participating in partnerships with:
The Québec Consortium for Drug Discovery (CQDM) is a meeting ground for all stakeholders in biopharmaceutical research and whose principal mission is to fund research projects carried out in partnership between the academic and hospital milieus in the public sector and the pharmaceutical and biotechnology industries in the private sector.
To identify genomic biomarkers useful for individualized treatment in cardiovascular disease, a study carried-out in parallel with a Phase III clinical trial of Dalcetrapib for treating stable coronary heart disease patients with recent acute coronary syndrome (total project cost $3 mm).
To identify genomic biomarkers useful for predicting the efficacy and safety of Ivabradine in the large-scale SIGNIFY clinical trial (total project cost $6 mm).
To develop and validate genomic biomarkers with potential use as part of a companion diagnostic for the drug Torceptrapib (Illuminate trial halted) (total project cost $2.5 mm).
For a large-scale study of the pharmacogenomics of cardiovascular disease and the identification of biomarkers useful in the prediction of statin response and myotoxic phenotype (total project cost $21 mm).
To identify genetic predictors of INR fluctuations in patients treated with warfarin and develop genetic tools for optimizing warfarin dosing (total project cost $2 mm).
For improved identification and treatment of rare inherited arrhythmias (total project cost $1.5 mm).
To establish relationships between biomarkers (genomic and metabolomic), imaging endpoints and clinical outcomes useful in the diagnosis and treatment of cardiovascular and cerebrovascular disease (total project cost for Phase I, sample collection $0.75 mm).
To develop and validate a proteomic biomarker for use in the diagnosis and treatment of arthrosclerosis
(total project cost $0.5 mm).